Market Overview

NovaBay Pharmaceuticals to Present at H.C. Wainwright 20th Annual Global Investment Conference on September 6

Share:

NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a
biopharmaceutical company focusing on commercializing prescription
Avenova® for the domestic eye care market, announces that
management is scheduled to present a corporate overview at the H.C.
Wainwright 20th Annual Global Investment Conference on
Thursday, September 6, 2018 at 2:35 p.m. Eastern time (5:35 p.m. Pacific
time). The conference is being held at the St. Regis New York in New
York City.

A live webcast and replay will be available on the Investors section of
the Company's website at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on
commercializing and developing its non-antibiotic anti-infective
products to address the unmet therapeutic needs of the global, topical
anti-infective market with its two distinct product categories: the
NEUTROX® family of products and the AGANOCIDE®
compounds. The Neutrox family of products includes AVENOVA®
for the eye care market, NEUTROPHASE® for wound care market,
and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target applications
in the dermatology and urology markets.

Socialize and Stay informed on NovaBay's progress:
Like
us on 
Facebook
Follow
us on 
Twitter
Connect
with NovaBay on 
LinkedIn
Join
us on 
Google+
Visit NovaBay's Website

View Comments and Join the Discussion!